Medicus Pays $27 Million for Pfizer Cancer Drug Rights
CONSHOHOCKEN, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) agreed Wednesday to pay Pfizer Inc. $27 million for worldwide rights to an early-stage antibody-drug conjugate, taking control of CD228V’s development while …
Medicus Pays $27 Million for Pfizer Cancer Drug Rights Read More